Literature DB >> 29056882

Effects of Testosterone on Benign and Malignant Conditions of the Prostate.

Amin S Herati1,2, Taylor P Kohn2, Peter R Butler1,2, Larry I Lipshultz1,2.   

Abstract

PURPOSE OF THE REVIEW: This review summarizes the current literature regarding the effects of testosterone therapy (TTh) on common disorders of the prostate. RECENT
FINDINGS: Testosterone therapy has gained credibility over the last several decades as a potentially safe co-treatment modality for men with benign and malignant prostatic conditions. Our understanding of the effects of testosterone on the prostate continues to evolve with ongoing clinical and basic science research. Findings of these studies have reinvigorated the debate over the effects of testosterone on benign and malignant disorders of the prostate, including BPH, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and prostate cancer.
SUMMARY: Despite the burgeoning body of data claiming the safety and efficacy of TTh in common prostatic conditions (including BPH, CP/CPPS, and prostate cancer), diligent monitoring, appropriate patient selection, and informed consent are critical until more definitive studies are performed.

Entities:  

Keywords:  Adult; QoL; androgen deprivation; benign prostatic hyperplasia; chronic pelvic pain syndrome; chronic prostatitis; humans; prostate cancer; prostate-specific antigen/serum; sex hormones; testosterone; treatmet outcome

Year:  2017        PMID: 29056882      PMCID: PMC5648355          DOI: 10.1007/s11930-017-0104-7

Source DB:  PubMed          Journal:  Curr Sex Health Rep        ISSN: 1548-3584


  65 in total

Review 1.  Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.

Authors:  Alvaro Morales
Journal:  BJU Int       Date:  2011-05       Impact factor: 5.588

2.  Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty.

Authors:  Anne M Kenny; Alison Kleppinger; Kristen Annis; Margaret Rathier; Bruce Browner; James O Judge; Daniel McGee
Journal:  J Am Geriatr Soc       Date:  2010-06       Impact factor: 5.562

3.  Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume.

Authors:  A V Pechersky; V I Mazurov; V F Semiglazov; A I Karpischenko; V V Mikhailichenko; A V Udintsev
Journal:  Int J Androl       Date:  2002-04

4.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

5.  Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia.

Authors:  Eduard García-Cruz; Marta Piqueras; Maria José Ribal; Jorge Huguet; Rodrigo Serapiao; Lluis Peri; Laura Izquierdo; Antonio Alcaraz
Journal:  BJU Int       Date:  2012-01-18       Impact factor: 5.588

6.  Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men.

Authors:  S Holmäng; P Mårin; G Lindstedt; H Hedelin
Journal:  Prostate       Date:  1993       Impact factor: 4.104

7.  Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.

Authors:  Brian R Lane; Andrew J Stephenson; Cristina Magi-Galluzzi; Milton M Lakin; Eric A Klein
Journal:  Urology       Date:  2008-08-09       Impact factor: 2.649

8.  Mechanisms in prostatitis/chronic pelvic pain syndrome.

Authors:  Michel A Pontari; Michael R Ruggieri
Journal:  J Urol       Date:  2008-05       Impact factor: 7.450

9.  Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.

Authors:  Eduardo García-Cruz; Marta Piqueras; Jorge Huguet; Lluis Peri; Laura Izquierdo; Mireia Musquera; Agustin Franco; Ricardo Alvarez-Vijande; Maria Jose Ribal; Antonio Alcaraz
Journal:  BJU Int       Date:  2012-05-15       Impact factor: 5.588

Review 10.  Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Int J Biol Sci       Date:  2016-02-06       Impact factor: 6.580

View more
  3 in total

Review 1.  Androgen action in prostate function and disease.

Authors:  Partha P Banerjee; Subhadra Banerjee; Terry R Brown; Barry R Zirkin
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

2.  Impact of sex, body mass index and initial pathologic diagnosis age on the incidence and prognosis of different types of cancer.

Authors:  Xuan Huang; Chuanjun Shu; Li Chen; Bing Yao
Journal:  Oncol Rep       Date:  2018-06-27       Impact factor: 3.906

3.  Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome.

Authors:  Kevin Pineault; Shagnik Ray; Andrew Gabrielson; Amin S Herati
Journal:  Transl Androl Urol       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.